Africa's Pharma Sovereignty at Risk: How Europe's Reshoring Could Drain Global API Supply

The European Union's Critical Medicines Act (CMA) is designed to strengthen Europe's pharmaceutical resilience by encouraging the regional production and stockpiling of Active Pharmaceutical Ingredients (APIs) and essential medicines. While the initiative aims to improve medicine security within Europe, some health policy experts have raised concerns about its potential impact on global pharmaceutical supply chains.

One concern is that increased European demand for APIs could tighten global markets, potentially increasing prices and making it more challenging for emerging pharmaceutical manufacturing regions including parts of Africa to secure affordable raw materials. The African Union has been promoting local pharmaceutical production to reduce import dependence, and shifts in global API availability could influence these long-term development efforts.

For pharmaceutical manufacturers, procurement professionals, and healthcare organizations, understanding these evolving supply chain dynamics is important for future sourcing and investment decisions.

Why API Availability Matters Globally

Active Pharmaceutical Ingredients form the foundation of medicine manufacturing.

Reliable API access supports:

• Generic medicine production

• Essential drug manufacturing

• Healthcare security

• Stable pharmaceutical supply chains

• Affordable medicine availability

• Regional manufacturing growth

Changes in global API demand can influence procurement strategies across multiple regions.

In addition to APIs, pharmaceutical manufacturers rely on essential excipients and processing chemicals such as Propylene Glycol (USP Grade), Polyethylene Glycol (PEG), Mannitol, Citric Acid, Sorbitol, Glycerin, and Isopropyl Alcohol (IPA). Stable global availability of these pharmaceutical ingredients is equally important for maintaining consistent medicine production across different regions.

Europe's Reshoring Strategy

The Critical Medicines Act seeks to strengthen Europe's pharmaceutical resilience by encouraging greater regional production.

Its objectives include:

• Expanding European API manufacturing

• Improving medicine availability

• Strengthening supply chain resilience

• Reducing import dependence

• Supporting strategic stockpiles

• Encouraging pharmaceutical investment

These initiatives are intended to improve long-term healthcare security across the European Union.

Potential Implications for Emerging Markets

As pharmaceutical production expands in different regions, procurement teams should monitor changes in supply availability and market dynamics.

Possible considerations include:

• Competition for API supply

• Changes in global pricing

• Regional manufacturing investment

• Supplier diversification

• Long-term procurement planning

• Strategic inventory management

The actual impact will depend on future manufacturing capacity, investment levels, and how global API production evolves over time.

Procurement Considerations

Pharmaceutical procurement professionals should prepare for a changing global sourcing landscape.

Key priorities include:

• Building diversified supplier networks

• Maintaining long-term supplier relationships

• Monitoring regional manufacturing developments

• Evaluating supply chain risks

• Strengthening inventory planning

• Expanding qualified supplier options

A balanced procurement strategy helps improve resilience while reducing dependence on any single production region.

Looking Ahead

The expansion of pharmaceutical manufacturing in Europe, Africa, and other regions reflects a broader global trend toward stronger healthcare supply chains. Rather than replacing global trade, regional manufacturing initiatives may gradually complement existing supply networks by improving resilience and reducing vulnerabilities.

For procurement teams, maintaining diversified sourcing strategies and monitoring regional investment trends will remain essential as pharmaceutical manufacturing continues to evolve.

Key Takeaways

• The EU's Critical Medicines Act aims to strengthen regional API production.

• Increased regional demand could influence global API market dynamics.

• Emerging pharmaceutical manufacturing regions are continuing to expand production capabilities.

• Procurement teams should diversify suppliers and monitor market developments.

• Flexible sourcing strategies support long-term pharmaceutical supply resilience.